ABOUT SINOBIOPHARM
-
0+The number of R&D
team members(2021) -
0+Number of group patents
authorized by the end of 2021 -
0%Ratio of R&D investment
to revenue in 2021 -
0%Revenue growth in 2021 compared
to the same period last year



News Center
-
CHINADAILY|Sino Biopharm announces clinical trials for pneumoconiosis drug
Sino Biopharmaceutical Limited, or Sino Biopharm, a leading innovative research and development-driven pharmaceutical conglomerate in China, announced on Tuesday that TDI01 suspension, an innovative drug independently developed by its subsidiary Beijing Tide Pharmaceutical Co Ltd, had received approval from the National Medical Products Administration for clinical trials on treating pneumoconiosis, a key occupational disease in China that affects the lungs and is caused by inhalation of dust.View -
“Tolvaptan Tablets” obtains Drug Registration Certificate
Recently, “Tolvaptan Tablets” (Brand name: Xinsuan), a new diuretic drug developed by the Group, has obtained drug registration certificate granted by the National Medical Products Administration of the People’s Republic of China and is deemed to have passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs.View -
“Sunitinib Malate Capsules” obtains Drug Registration Certificate
Recently, “Sunitinib Malate Capsules” (brand name: Qingnishu (晴尼舒)) (approved specification: 12.5mg), a key product in the field of oncology developed by the Group, has obtained the drug registration certificate from the National Medical Products Administration of the People’s Republic of China.View -
“Aprepitant Capsules” obtains Drug Registration Certificate
Recently, “Aprepitant Capsules” (brand name: “Shanyi” (善依)) (approved specifications: 80mg and 125mg), an adjuvant drug for tumor treatment developed by the Group, has obtained the drug registration certificate from the National Medical Products Administration of the People’s Republic of China.View

Based on independent innovation, introduce global innovative technology